Slow going for CompCom’s health market inquiry
South Africa’s private healthcare industry is patiently awaiting news or findings from the Competition Commission’s (CompCom) health market inquiry (HMI).
Following concerns about how private healthcare functions in South Africa, given healthcare expenditure and prices rising above headline inflation, the CompCom began an inquiry into the sector.
The HMI started on January 6 2014, aiming to be finalised by November 2015. It was then extended to December 2016. However, due to the size and complexity of the report, and delays from stakeholders in providing data, it was extended by another year.
Chair of the South African Medical Association (Sama) Dr Mzukisi Grootboom, told Moneyweb some outstanding issues still needed to be addressed and the HMI had to look at data submitted by certain parties.
Aside from some updates provided in December 2016, relating to claims data and a summary of consumer survey results among other items, no detailed recommendations or findings have been released as yet.
The only recent feedback from the HMI is that it’s considering granting “a restricted group of external advisors” access to confidential information from medical schemes that was used to construct expenditure analysis reports.
The revised timetable, published in December, reads as follows:
- there should be public hearings in May and June this year;
- the provisional findings report and conditional recommendations should be published on September 1;
- during September stakeholder comments on the provisional report and recommendations are to be received;
- and the final report and recommendations are to be published on December 15 2017.
This is in addition to the expectation of several specific reports.
Esmé Prins-Van den Berg, HealthCare Navigator consultant, writing for Anglo Medical Scheme here, says the following issues were raised by stakeholders in written submissions and public hearings:
- PMBs: too restrictive and too open-ended regarding reimbursement;
- no transparency in selection of designated service providers (DSPs);
- lack of information on quality of care by providers;
- absence of tariff benchmarks and of an oversight mechanism for clinical coding;
- imbalance of bargaining power among stakeholders;
- disadvantage by small players in various relationships regarding bargaining power, DSPs;
- hospital licensing;
- provider and funder relationships; and
- uncertainty regarding NHI.
Expectations and concerns
Says Sama’s Grootboom: “While we are in support of the process, as we believe it will once and for all give us an indication of the real cost drivers in the private health sector, we have great concerns that it might just be a smoke screen for a predetermined outcome.
“We are waiting, with keen interest, for the release of the final report.”
According to Prins-Van den Berg, the report is expected to address aspects such as:
- collective bargaining mechanisms and/or the determination of benchmark tariffs for the sector;
- establishing a process or authority to deal with clinical coding-related issues;
- mechanisms to address information asymmetry;
- publication of data on quality, especially regarding providers; and
- other recommendations to enhance competition e.g. regarding oligopolies.
“There is competition where there shouldn’t be and none where there should be - which results in high costs and indifferent quality,” says Dr Brian Ruff, CEO of PPO Serve, and Discovery Health’s former head of clinical risk. Ruff presented at the HMI last year.
“That is, we currently have destructive competition between individual clinicians who should instead be collaborating in teams organised around the patient needs. Competition should be between local teams in systems, based on the quality of their outcomes and costs.”
Ruff explains that ideal outcomes from the HMI would be for mandatory data and interoperability (IT information exchange and use) standards throughout. Schemes should compete in regions (not nationally), with size caps to prevent dominance and guarantee competition; scheme licences should be reviewed every five years; and ‘for-profit’ schemes should be allowed, with a regulated claims pay-out ratio.
Regarding healthcare providers, a new supply-side regulator should be created with policy that maximises efficiency. There should also be incentives and support for new team-based delivery models, he adds.